Skip to main content

Ushering in a new era for treating diseases with high unmet needs

Rooted in Connection

We have an audacious mission to develop novel therapies for communities with high unmet needs. Where others see obstacles, the Amylyx team sees opportunities to find solutions for some of medicine’s toughest challenges.

We have the experience, the integrity, and the drive to deliver with all possible speed and rigor — because we know individuals and families are counting on us.

Our Company

Our Company

We are rooted in connections: between our company and the communities we serve, between questions and solutions, and between insights and actions. We see a path between where we are and where we need to be. Learn more about the history and team that serve as a critical foundation for what we’ve set out to accomplish next.

Amylyx co-CEOs Josh Cohen and Justin Klee at an ALS community walk.

Our Science

Computer-generated image of purple and blue neurons that are illuminated by twisting, neon pink strands that form a path of light.

Our Science

We chart new territories with rigorous science. We are advancing a pipeline in which we’ve matched investigational therapies with diseases where they can make the greatest impact, based on well-defined mechanistic rationale, clear clinical outcomes and biomarkers, and rigorous preclinical data, agnostic of modality.

Community

Employees posing at Amylyx' office with guests from the community.

Community

At the center of each of our decisions are people living with serious diseases, their support systems, and their loved ones with legacies to carry on. Our commitment is more than just a promise to work with urgency; it’s a personal responsibility.

Working at Amylyx

Working at Amylyx

Our mission would not be possible without each individual perspective within our talented organization. Amylyx has created a culture of caring and assembled an experienced team ready to take action on behalf of and alongside people living with high unmet needs.

Employees engaging in a group session at Amylyx' company-wide meeting.

Latest News